[Skip to Content]
[Skip to Content Landing]
August 20, 1982

New trials to further evaluate intracoronary use of streptokinase

JAMA. 1982;248(7):805-806. doi:10.1001/jama.1982.03330070003001

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Intracoronary streptokinase thrombolysis will be evaluated in a major randomized study that could begin before the end of summer at Mount Sinai School of Medicine, New York University-affiliated Bellevue Hospital Center, and the City Hospital Center at Elmhurst, all in the New York City area.

The study will be supported by the National Heart, Lung, and Blood Institute (NHLBI), Bethesda, Md, which also is considering an even larger 10- to 12-center study that could begin next year. The trial that already has been approved probably will require at least five years to complete and will cost an estimated $3 million.

Streptokinase is an enzyme harvested from laboratory cultures of group C β-hemolytic streptococci. Medical interest in this bacterial protein dates from at least 1933, when William S. Tillett, MD, and Raymond L. Garner, PhD, both of Johns Hopkins University, Baltimore, observed that it could dissolve human blood clots.

By 1977,